Seeking Alpha

Acadia Pharmaceuticals (ACAD +0.4%) says data from a Phase III trial of pimavanserin suggest the...

Acadia Pharmaceuticals (ACAD +0.4%) says data from a Phase III trial of pimavanserin suggest the treatment is well-tolerated and effective when administered long-term. (See also: JMP, SA contributor weigh in on ACAD)
Comments (1)
  • How far up can the PPS of ACAD go?
    18 Jun 2013, 09:53 AM Reply Like
DJIA (DIA) S&P 500 (SPY)